Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 61, 2001 - Issue 6
Submit an article Journal homepage
45
Views
40
CrossRef citations to date
0
Altmetric
Research Article

Vasoactive substances in the circulatory dysfunction of cirrhosis

S. Møller, Departments of Clinical Physiology
,
F Bendtsen Gastroenterology, Hvidovre Hospital, University of Copenhagen,Hvidovre,Denmark
&
J. H. Henriksen Departments of Clinical Physiology
Pages 421-429 | Published online: 08 Jul 2009

  • Schrier RW, Fassen RG, Ohara M, Martin PY. Pathophysiology of renal fluid retention. Kidney Int 1998; 54: S127-32.
  • Moller S, Henriksen JH. The systemic circulation in cirrhosis. In: Arroyo V, Gines P, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. Maiden: Blackwell; 1999. p. 307-29.
  • Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32: 157-70.
  • Arroyo V, Gines P. Arteriolar vasodilatation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. Gastroenterology 1992; 102: 1077-9.
  • Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiologyand clinical consequences. Hepatology 1994; 20: 1359-63.
  • Sherlock S. Vasodilatation associated with hepatocellular disease: relation to functional organ failure. Gut 1990;31:365-7.
  • Mø11er S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996; 56: 481-90.
  • Pateron D, Tazi KA, Sogni P, Heller J, Chagneau C, Poirel O, Philippe M, Moreau R, Lebrec D. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 2000; 119: 196-200.
  • Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991; 12: 118-23.
  • Bernardi M, Trevisani F, Gasbarrini G. The reninangiotensin-aldosterone system in liver disease. In: Bomzon A, Blendis LM, editors. Cardiovascular complications of liver disease. Boca Raton: CRC Press; 1990. p. 29-62.
  • Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998; 29: 328-41.
  • Møller S, Christensen E, Henriksen JH. Continuous blood pressure monitoring in cirrhosis -- relations to splanchnic and systemic haemodynamics. J Hepatol 1997; 27: 284-94.
  • Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Arterial compliance in patients with cirrhosis. High stroke volume/pulse pressure ratio as an index of elevated arterial compliance. Am J Physiol 2001; 280: G594.
  • Blendis L, Wong F. Is there a cirrhotic cardiomyopathy? Am J Gastroenterol 2000; 95: 3026-8.
  • Schrier RW, Niederberger M, Weigert A, Gines P. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Sem Liver Dis 1994; 14: 14-22.
  • Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104: 1750-4.
  • Sogni P, Sabry S, Moreau R, Gadano A, Lebrec D, Dinhxuan AT. Hyporeactivity of mesenteric resistance arteries in portal hypertensive rats. J Hepatol 1996; 24: 487-90.
  • Jimenez W, Rodes J. Impaired responsiveness to endogenous vasoconstrictors and endotheliumderived vasoactive factors in cirrhosis. Gastroenterology 1994; 107: 1201-3.
  • SaIo J, Gines A, Quer JC, Femandez-Esparrach G, Guevara M, Gines P, Bataller R, Planas R, Jimenez W, Arroyo V, Rodes J. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996:25:916-23.
  • Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998; 58: 361-72.
  • Laffi G, Lagi A, Cipriani M, Barletta G, Bernardi L, Fattorini L, Melani L, Riccardi D, Bandinelli G, Mannelli M, Lavilla G, Gentilini P. Impaired cardiovascular autonomie response to passive tilting in cirrhosis with ascites. Hepatology 1996; 24: 1063-7.
  • Trevisani F, Sica G, Mainqua P, Santese G, De Notariis S, Caraceni P, Domenicali M, Zaca F, Grazi GL, Mazziotti A, Cavallari A, Bernardi M. Autonomie dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999; 30: 1387-92.
  • Gupta S, Morgan TR, Gordan GS. Calcitonin gene-related peptide in hepatorenal syndrome. J Clin Gastroenterol 1992; 14: 122-6.
  • Møller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand J Gastroenterol 1996; 31: 928-33.
  • Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997:26:1111-9.
  • Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment. Oxford: Black well; 1994. p. 17-26.
  • Guevara M, Gines P, Jimenez W, Sort P, Fernandezesparrach G, Escorsell A, Bataller R, Bosch J, Arroyo V, Rivera F, Rodes J, Fernandez-Esparrach G. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114: 336-43.
  • La Villa G, Laffi G, Gentilini P. Atrial natriuretic peptide and other natriuretic factors in cirrhosis. In: Arroyo V, Gines P, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. Maiden: Blackwell; 1999. p. 231-48.
  • Gerbes AL, Wernze H, Arendt RM, Riedel A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology 1989; 9: 417-22.
  • Salerno F, Badalamenti S, Moser P, Lorenzano E, Incerti P, Dioguardi N. Atrial natriuretic factor in cirrhotic patients with tense ascites. Effect of largevolume paracentesis. Gastroenterology 1990; 98: 1063-70.
  • La Villa G, Riccardi D, Lazzeri C, Casini RV, Dello SA, Tosti GC, Fronzaroli C, Foschi M, Laffi G, Gentilini P. Blunted natriuretic response to lowdose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. Hepatology 1995; 22: 1745-50.
  • Salo J, Jimenez W, Kuhn M, Gines A, Gines P, Fernandez-Esparrach G, Angeli P, Claria J, Bataller R, Arroyo V, Forssmann WG, Rodes J. Urinary excretion of urodilatin in patients with cirrhosis. Hepatology 1996; 24: 1428-32.
  • Gulberg V, Møller S, Henriksen JH, Gerbes AL. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 2000; 47: 852-7.
  • Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, Jimenez W, Gaya J, Rivera F, Rodes J. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
  • Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, Cardenas A, Guevara M, Sort P, Jimenez W, Bataller R, Arroyo V, Rodes J. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
  • M011er S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-25.
  • Henriksen JH, Bendtsen F, Sørensen TIA, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-13.
  • Gentilini P, Romanelli RG, Laffi G, Barletta G, Delbene R, Messeri G, Lavilla G. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol 1999; 30: 632-8.
  • Henriksen JH, Møller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J Hepatol 1999; 31: 712-8.
  • Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to elevated circulating calcitonin generelated peptide (CGRP) and low adrenaline, but not to activated vasoconstrctor systems. Gut 2001; 49: 112-8.
  • Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, Kaplan MM. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998; 43: 1701-7.
  • Laffi G, Barletta G, Lavilla G, Delbene R, Riccardi D, Ticali P, Melani L, Fantini F, Gentilini P. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113: 891-8.
  • Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci 1999; 97: 259-67.
  • Møller S. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Dan Med Bull 1998; 45: 1-14.
  • Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34.
  • Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24: 451-9.
  • Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Pailla M, Grassi G, Giannattasio C, Mancia G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-7.
  • Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossie M. Cardiac function and haemo-dynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-8.
  • Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6: S44-52.
  • Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, Moreau R, Langtet P, Elman A, Bernuau J, Valla D, Erlinger S, Lebrec D. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640-3.
  • Moreau R, Komaichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994; 106:1016-23.
  • Zavecz JH, Bueno O, Maloney RE, O'Donnell JM, Roerig SC, Battarbee HD. Cardiac excitation-contraction coupling in the portal hypertensive rat. Am J Physiol Gastrointest L 2000; 279: G28-39.
  • Christensen PK, Gall MA, Major-Pedersen A, Sato A, Rossing P, Breum L, Pietersen A, Kastrup J, Parving HH. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 2000; 60: 323-32.
  • Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997; 273: G537-44.
  • Ma ZH, Zhang YK, Huet PM, Lee SS. Differential effects of jaundice and cirrhosis on betaadrenoceptor signaling in three rat models of cirrhotic cardiomyopathy. J Hepatol 1999; 30: 485-91.
  • Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000; 118: 937-44.
  • Qi W, Kjekshus J, Hall C. Differential responses of plasma atrial and brain natriuretic peptides to acute alteration in atrial pressure in pigs. Scand J Clin Lab Invest 2000; 60: 55-63.
  • Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726-48.
  • Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 1988; 6: 350-8.
  • Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders. Role of the renin-angiotensin-aldosterone system. Sem Liver Dis 1994; 14: 23-34.
  • Henriksen JH, Bendtsen F, Gerbes AL, Christensen NJ, Ring-Larsen H, Sørensen TIA. Estimated central blood volume in cirrhosis --relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16: 1163-70.
  • Bettencourt P, Ferreira A, Dias P, Castro A, Martins L, Cerqueira-Gomes M. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 2000; 93: 19-25.
  • Cowie MR. BNP: soon to become a routine meas- ure in the care of patients with heart failure? Heart 2000; 83: 617-8.
  • Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
  • Schulz H, Langvik TA, Lund SE, Smith J, Ahmadi N, Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest 2001; 61: 33-42.
  • Muders F, Kromer EP, Griese DP, Pfeifer M, Hense HW, Riegger GA, Eisner D. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442-9.
  • Hughes D, Talwar S, Squire IB, Davies JE, Ng LL. An immunoluminometric assay for N-terminal probrain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci (Colch) 1999; 96: 373-80.
  • Henriksen JH, Bendtsen F, Schutten J, Warberg J. Hepatic-intestinal disposal of endogenous human alpha natriuretic factor in patients with cirrhosis. Am J Gastroenterol 1990; 85: 1155-9.
  • Yoshimura M, Mizuno Y, Harada E, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Soejima H, Miyamoto S, Takazoe K, Ogawa H, Kugiyama K, Saito Y, Nakao K, Yasue H. Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure. Metabolism 2000; 49: 1228-33.
  • Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000; 167: 239-46.
  • Burnett JC, Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl 1999; 17: S37-43.
  • McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 1997; 43: 329-32.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.